@openFDA and its related website launched February 27.
Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?
The drugmaker says researchers will be able to view patient-level data and promises less jargon-filled summaries by year-end.
The new label will reflect the RA pill's superiority to methotrexate and placebo in inhibiting the progression of structural joint damage.
Phase-III results, top-lined today, show Lilly's investigational GLP-1 drug is well-positioned to eat into the multi-billion-dollar diabetes market now dominated by Novo Nordisk.
The drugmaker revealed efficacy data that analysts say could prompt the health agencies to emphasize adult vaccination.
The drugmaker was scant on details, but Phase-III ramucirumab results among non-small cell lung cancer patients showed increased overall and progression-free survival vs. placebo.
A report published by JAMA indicated that online reviews sway a percentage of patients, but that personal recommendations hold more weight.
The school will act as an independent panel for the drug maker, reviewing requests from investigators for access to anonymized, clinical-trial data.
A young company is hoping its analytics platform can help doctors and pharma figure out who's going to stop taking their medication, and get them back on track.
Positive results from a Phase-III trial edge Amgen's evolocumab closer to approval, though it's still behind rivals in the PCSK9 race.
The data and analytics giant is looking to launch an IPO. The company, which is the subject of an antitrust suit, said in its prospectus that it anticipates future acquisitions.
Mid-stage data show the drug, romosozumab, was associated with significant increases in bone mineral density compared to Lilly's Forteo and off-patent Fosamax.
Our year-end list captures the 10 that sparked heaviest interest.
Kalydeco failed to hit its primary endpoint of significantly improving lung function in a subset of CF patients, but some did show a benefit.
Sovaldi is already approved for most patients with HCV, but its marketer may have earned itself some breathing room against rivals in the next stage of the all-oral hep. C arms race.
A recent poll shows a strong desire among web-savvy patients to play a more active role in medical research.
Sanofi top-lined positive clinical data today from its investigational basal insulin, as it seeks to defend its position in this fast-growing segment.
Research suggests ADHD is becoming a regular fixture in adolescence. At the same time, publishers and startups have developed increasingly complex tools to separate patients from abusers.
A poll indicates new cholesterol guidelines won't shake up the statin market in 2014.
A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.
New results from its Phase II safety trial show the LDL-cholesterol lowerer was not associated with a major increase in adverse events vs. standard of care.
Most patients would advise today's FDA Lemtrada panel to allow doctors to gauge the drug's risk-benefit profile, although there was strong sentiment on either side of the issue.
An investigational cardiovascular heart drug failed to reduce the risk of heart attack or stroke, a miss which some on Wall Street say raises questions about the drugmaker's ability to deliver in late-stage trials.
Safety reviewers' reservations about the MS drug's risk profile, unveiled in briefing documents ahead of an ad-com meeting, suggest it won't be smooth sailing for the drug in the US.
Data released at the Boston meeting of the American Association for the Study of Liver Diseases hints at an upcoming Gilead-Merck brawl.
Researchers found that most healthcare apps have limited functionality, don't serve patients with multiple needs, and taper off when support is needed most. No wonder adoption is low.
Researchers say the drug class could be linked to a lower autoimmune risk among diabetics.
The AAP says greater access and education are critical in curbing STIs.
It was a 15-0 vote for Gilead's sofosbuvir in hep. C. The expedited PDUFA date: Dec. 8. Janssen's simeprivir was endorsed the day before.